-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
SARS-CoV-IN-4
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2445585-37-3.gif)
| Category | SARS-CoV |
| CAS | 2445585-37-3 |
| Description | SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14). SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals. |
Product Information
| Synonyms | SARS-CoV-IN-4|CHEMBL4793508|BDBM50565050|HY-143467|CS-0438280 |
| Molecular Weight | 779.14 |
| Molecular Formula | C28H31ClN12O11S |
| Canonical SMILES | C1=CC(=C(C=C1S(=O)(=O)N(CCOC2C(C(OC2N3C=NC4=C(N=CN=C43)N)CO)O)CC5C(C(C(O5)N6C=NC7=C(N=CN=C76)N)O)O)[N+](=O)[O-])Cl |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 1390 |
| Exact Mass | 778.1644487 |
| In Vitro | SARS-CoV-IN-4 (compound 13) shows inhibitory activity on N7-MTases, with inhibition at 50 μM of 97.2 ± 2.7% (SARS-CoV nsp14), and 33.9 ± 3.3% (hRNMT), respectively. SARS-CoV-IN-4 stabilizes SARS-CoV nsp14 against thermal denaturation with a ΔTm +10.8 °C and exhibits notable binding affinity (apparent KD 1.3 ± 0.87 μM). |
| Target | IC50: 0.6 ± 0.1 μM (SARS-CoV nsp14), 247.5 ± 14.9 μM (hRNMT) |
| XLogP3-AA | -2.1 |
